Novo Nordisk files for FDA OK of fast-acting insulin

Hard on the heels of Eli Lilly's ($LLY) decision to abandon insulin peglispro, rival Novo Nordisk ($NVO) is moving ahead with its faster-acting insulin aspart, filing for FDA approval of the mealtime insulin for diabetes. The insulin was studied in some 2,100 adults with Type 1 and Type 2 diabetes. Novo filed in the EU last week. "Today's filing of faster-acting insulin aspart is a step forward in strengthening our mealtime insulin offerings for patients who require mealtime blood sugar control," said Dr. Todd Hobbs, U.S. chief medical officer of Novo Nordisk. "Faster-acting insulin aspart underscores our continued commitment to developing new treatment options for these patients. We look forward to working closely with the FDA on the submission and are focused on bringing the next generation of our mealtime insulin to market." Release

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.